DCM
VRCA icon

Diag Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Diag Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$937K Buy
+11,495
New +$1.4M 1.07% 30

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CI
Conning Inc Hartford, Connecticut $3.34B AUM 25.19% 1-Year Est. Return

Diag Capital Management's VRCA Position: Q4 2018 in Review

Diag Capital Management opened a new position in Verrica Pharmaceuticals (VRCA) in Q4 2018: 11,495 shares worth $937K. The stake represents 1.07% of the portfolio and ranks #30 among its holdings.

40 funds tracked by Wall St. Rank hold VRCA as of Q4 2018.

  • Diag Capital Management held 11,495 shares of Verrica Pharmaceuticals worth $937K as of Q4 2018.
  • Verrica Pharmaceuticals was a new Diag Capital Management position in Q4 2018.
  • Verrica Pharmaceuticals made up 1.07% of Diag Capital Management's portfolio in Q4 2018, its #30 holding.
  • 40 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.